Myoungil Cha - 20 May 2026 Form 4 Insider Report for TANDEM DIABETES CARE INC (TNDM)

Reporting relationship: Director
Issuer ticker: TNDM
Reported as of: 20 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 May 2026, 16:04:42 UTC
Prior SEC filing: 18 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Jerilyn Laskie, Attorney-in-Fact for Myoungil Cha

Key filing fact

Myoungil Cha filed Form 4 for TANDEM DIABETES CARE INC (TNDM) on 22 May 2026.

Key facts

This page summarizes Myoungil Cha's Form 4 filing for TANDEM DIABETES CARE INC (TNDM).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 22 May 2026, 16:04.

Change

Previous filing in this sequence was filed on 18 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001934068 Primary reporting owner

Cha Myoungil

Relationship: Director
Address: 12400 HIGH BLUFF DRIVE, SAN DIEGO
Signature: /s/ Jerilyn Laskie, Attorney-in-Fact for Myoungil Cha
Signature date: 22 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TNDM transaction

Common Stock

Options Exercise

Transaction value
Shares: +8,759
Change %: +64%
Price: $0.000000^*
Shares after: 22,458
Date: 21 May 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TNDM transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +10,220
Change %
Price: $0.000000^*
Shares after: 10,220
Date: 20 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,220
Exercise price
Footnotes: F1, F2

TNDM transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
Shares: -8,759
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 21 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,759
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

Footnote F2

Such RSUs were granted to the Reporting Person on May 20, 2026, and will vest on the one-year anniversary thereof, subject to the terms of the 2023 Plan.

Footnote F3

On May 21, 2025, the Reporting Person was granted 8,759 RSUs, all of which vested and converted into shares of the Issuers common stock on the one-year anniversary thereof in accordance with the 2023 Plan.

SEC remarks

Ex. 24: Power of Attorney